Pine Bark and Blood Pressure: A Signal That Needs Proof

Pine bark produced an intriguing blood-pressure signal. It did not prove a treatment effect.

Different polyphenols have different chemical structures, so it is reasonable to ask whether they act differently in blood vessels. Pine bark contains oligomeric proanthocyanidins (OPCs), condensed tannin compounds that differ from olive-derived phenylethanol polyphenols such as hydroxytyrosol. The chemistry is real. The blood-pressure claim remains unproven.

The best direct study found that a supplement containing Pinus massoniana bark extract lowered systolic blood pressure within its treatment group over 12 weeks. Yet the trial's placebo-controlled comparisons never reached statistical significance. That second result decides the practical question: the study cannot show that pine bark caused the decline.

This is a useful case study in why an impressive-looking subgroup result can still fall short of evidence for a supplement. The numbers deserve attention; they do not deserve a sales page.

What the randomized trial found

In a 2022 randomized, placebo-controlled trial by Ferguson et al., 62 healthy adults aged 55 to 75 took either placebo or 1,322 mg per day of a polyphenol-rich dietary supplement containing Pinus massoniana bark extract for 12 weeks. Blood pressure was a secondary analysis rather than the parent trial's prespecified primary endpoint.

Within the overall pine-bark-supplement group, systolic blood pressure fell 3.29 mmHg from baseline to week 12 (p=0.028). Among participants whose baseline systolic pressure exceeded 120 mmHg, the within-group reduction was 6.46 mmHg (p=0.001). In the unmedicated members of that normal-high subgroup, systolic pressure fell 7.49 mmHg and diastolic pressure fell 3.06 mmHg (p=0.001 and p=0.011, respectively).

If those changes reflected a confirmed treatment effect, they could matter clinically. But the study did not report a statistically significant difference between the supplement and placebo groups at any time point, in the full sample or in any analyzed subgroup. The publication also required post-hoc power calculations, which means the trial was not designed to detect blood-pressure effects with adequate planned precision. No confidence interval for these estimates is available in the reported information here.

A before-and-after change can occur for many reasons: ordinary biological variation, changed behavior during a study, measurement variation, or regression to the mean. Randomization and a placebo group exist to separate those possibilities from an effect of the intervention. When the between-group comparison is null, a within-group p-value cannot fill the gap.

Why the largest subgroup result needs the most caution

The most dramatic decline appeared after progressive subgrouping: all supplement users, then those with systolic pressure above 120 mmHg, then those participants who were also unmedicated. That pattern could reflect a larger response among people with higher baseline pressure. It can also arise through regression to the mean.

People selected because one baseline reading sits above a cutoff tend, on average, to record lower values later even without treatment. The unmedicated normal-high subgroup likely included fewer than 20 people, although the exact subgroup size is not reported here. Small, unplanned subgroups generate unstable estimates and more opportunities for chance findings. The trial cannot distinguish a real subgroup response from those alternatives.

What pine bark chemistry can—and cannot—tell us

The chemical premise is sound. Zhou et al. characterized procyanidin oligomers from Pinus massoniana bark, including dimeric seco B-type derivatives such as gambiriin A1 and A2. These are OPC-class compounds, structurally distinct from the phenylethanol polyphenols associated with olive extracts.

That distinction makes different biological activity plausible. In vitro work on proanthocyanidins as a class has raised hypotheses involving endothelial nitric oxide synthase activation and reduced endothelin-1 signaling. Neither mechanism has been confirmed in people taking this specific P. massoniana formulation. No direct human measurements of eNOS phosphorylation, nitric-oxide bioavailability, or endothelin-1 after PMBE supplementation establish the proposed pathway.

There is limited human context for an endothelial effect. Belcaro et al. studied Pycnogenol, a French maritime pine bark extract, in adults recovering from COVID-19 and reported better endothelial-function and microcirculation markers than in a comparator group. This was an open, non-randomized, unblinded supplement study, not a blinded trial in healthy older adults. It supports a hypothesis about OPC-rich pine bark and vascular function; it does not validate PMBE for blood-pressure treatment.

Class-level evidence does not settle the extract-level question

A systematic review and meta-analysis by Lipert et al. found directional evidence that herbal supplements, including phenolic-rich interventions, can affect blood-pressure outcomes in adults with hypertension. Its available abstract does not provide pine-bark-specific effect sizes. A finding for a mixed category of herbal interventions cannot establish the effect of one bark extract in healthy people with normal to normal-high pressure.

Similarly, a 2025 meta-analysis of polyphenol-rich interventions found effects on inflammatory and oxidative-stress markers in adults who were overweight or obese. Those biomarkers sit upstream of vascular regulation, but they are not blood-pressure outcomes or proof of a particular mechanism. The population also differs materially from healthy adults aged 55 to 75.

For perspective, other nutrition interventions have broader blood-pressure evidence in older adults. A 2025 meta-analysis of l-citrulline supplementation and watermelon intake, covering 15 randomized trials and 415 participants, reported pooled reductions of 4.02 mmHg in systolic pressure and 2.54 mmHg in diastolic pressure. That does not make citrulline appropriate for every person, but it illustrates the difference between a pooled randomized evidence base and one secondary analysis with a null placebo comparison.

The verdict: interesting hypothesis, premature purchase

Current evidence does not support pine bark proanthocyanidins as a validated antihypertensive intervention for healthy older adults. Ferguson et al. found statistically significant within-group declines, but the placebo-controlled test was negative. The product was also a composite polyphenol-rich supplement, so even a genuine effect could not be assigned specifically to pine bark OPCs.

What would change the verdict? A larger preregistered randomized trial with blood pressure as the primary endpoint, a clearly characterized PMBE intervention, and a prespecified placebo-controlled analysis.

Until then, pine bark has a biologically plausible vascular story and one unresolved clinical signal. That is enough to justify research, not enough to claim blood-pressure lowering.